Key Points <\/p>\n
Interested in Moderna, Inc.? Here are five stocks we like better.<\/a> <\/p>\n<\/li>\n Marc Lichtenfeld of the Oxford Club highlights three healthcare plays across different time horizons: Moderna for traders, Pharvaris for the next year, and AbbVie as a long-term hold. <\/p>\n<\/li>\n Moderna surged 177% after positive Phase 3 melanoma data with Merck’s Keytruda, while Pharvaris awaits third-quarter CHAPTER-3 trial results for its hereditary angioedema drug. <\/p>\n<\/li>\n AbbVie has raised its dividend every year since its 2013 spinoff, with Skyrizi and Rinvoq sales offsetting Humira’s decline and pushing full-year revenue guidance to $67.6 billion. <\/p>\n<\/li>\n<\/ul>\n Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House’s latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market. The sector kept climbing anyway. <\/p>\n That gap between headline risk and price action is worth sitting with. Attention has been locked on AI and semiconductors all year, and meanwhile, healthcare and biotech have produced some of the largest single-name moves on the board. Marc Lichtenfeld of the Oxford Club sorts the opportunity by patience: one name for traders, one for the next 12 months, one to hold for a decade. <\/p>\n \u2192 GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue<\/a> <\/p>\n Why Rate Moves Barely Touch Healthcare <\/p>\n Lichtenfeld’s structural argument starts with the bond market. Healthcare is close to interest rate neutral, and the logic is blunt: if the 10-year yield runs to 5% or 6%, people don’t stop taking their medicine. <\/p>\n Balance sheets help too. Most biotechs aren’t loaded with debt, because pre-revenue companies can’t borrow against revenue they don’t have. They raise capital by selling equity or converts instead. That makes the sector a rare place where a hawkish surprise doesn’t reprice the whole group. <\/p>\n \u2192 GTA VI’s Console Problem Isn’t Take-Two’s Problem<\/a> <\/p>\n Moderna’s Melanoma Data Rewrote the Short-Term Trade <\/p>\n Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) reported that their Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary endpoint of recurrence-free survival in patients with completely resected stage IIB\u2013IV melanoma. <\/p>\n It was the first positive Phase 3 for an mRNA-based cancer therapy. Moderna closed up 177% at $174.38 the day it landed. The earlier Phase 2b work reduced the risk of recurrence or death by 49% versus Keytruda alone. Full Phase 3 numbers haven’t been released yet. <\/p>\n Story Continues <\/p>\n \u2192 Lululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story<\/a> <\/p>\n Shares cooled after the company priced $2.6 billion in convertible notes, and Lichtenfeld reads the consolidation as a bull flag. His timeline is deliberately tight. On a daily chart, he wants confirmation inside a week or two; if the move doesn’t materialize, the trade gets abandoned rather than nursed. Elevated short interest is the accelerant he’s watching, since forced covering can compound a breakout. <\/p>\n For anyone drawn to the long-term story, his suggestion is a starter position rather than a full one. Biotech stocks can sell off on good news when the good news is already expected. <\/p>\n Pharvaris Faces a Phase 3 Readout in a Consolidating Market <\/p>\n Pharvaris (NASDAQ: PHVS) is the name most investors haven’t heard of. The roughly $2.4 billion company expects topline CHAPTER-3 data in the third quarter for deucrictibant, an oral therapy for hereditary angioedema, a rare and potentially life-threatening swelling disorder. <\/p>\n Convenience is the wedge. Earlier trial work showed attack reductions in the mid-80% range, against roughly 44% for the approved oral prophylactic. An oral option that competes with injectables on efficacy is a real adherence advantage. <\/p>\n The M&A backdrop adds a second layer. Chiesi agreed to buy KalVista Pharmaceuticals at $27 a share, about a 40% premium to the prior close, and BioCryst Pharmaceuticals (NASDAQ: BCRX) acquired Astria Therapeutics in a deal valued near $700 million. Lichtenfeld doesn’t buy for takeouts, but he notes the space has a buyer pool. On strong data, he sees $50 as a floor case over the next year. On weak data, the stock falls hard. <\/p>\n AbbVie Keeps Proving the Doubters Wrong <\/p>\n AbbVie (NYSE: ABBV) is the long hold, and Lichtenfeld’s favorite healthcare name for income. Spun out of Abbott Laboratories (NYSE: ABT) in 2013, it has raised its dividend every year since, currently $1.73 per quarter for a yield near 2.7%. <\/p>\n The bear case was always Humira’s patent cliff. Instead, dividend growth kept compounding while the pipeline did the heavy lifting. Skyrizi cleared $5.5 billion in the second quarter, up 24%, and Rinvoq added $2.5 billion, up 25%, as Humira fell to $756 million. Management raised full-year revenue guidance to $67.6 billion. Technically, shares recently punched through the $240 area that had rejected them repeatedly. <\/p>\n Names like this are the core of what Lichtenfeld builds portfolios around, and readers who want his monthly income picks can find them in his Oxford Income Letter dividend research. <\/p>\n Where the Risk Actually Sits <\/p>\n Position sizing is the discipline that separates these three. Large-cap pharma like AbbVie or Eli Lilly (NYSE: LLY) can absorb a failed trial. A small or mid-cap with one lead asset can be cut in half overnight. <\/p>\n Watch the calendars, not the narratives. Moderna’s follow-through window is measured in days, Pharvaris hinges on a readout due within weeks, and AbbVie asks only that you sit still. <\/p>\n